Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer-Reference-Cited by-同舟云学术

Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer

Published:2024-02-20 Issue:7 Volume:51 Page:2070-2084
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Pougoue Ketchemen Jessica,Njotu Fabrice Ngoh,Babeker Hanan,Ahenkorah Stephen,Tikum Anjong Florence,Nwangele Emmanuel,Henning Nikita,Cleeren Frederik,Fonge Humphrey^ORCID

Funder

Institute of Cancer Research

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00259-024-06648-3.pdf

Reference52 articles.

1. Chhikara BS, Parang K. Global Cancer Statistics 2022: the trends projection analysis. Chem Biol Lett. 2022;10:451.

2. Latta EK, Tjan S, Parkes RK, O’Malley FP. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol. 2002;15:1318–25. https://doi.org/10.1097/01.mp.0000038462.62634.b1.

3. Woo S-K, Jang SJ, Seo M-J, Park JH, Kim BS, Kim EJ, et al. Development of 64Cu-NOTA-Trastuzumab for HER2 targeting: A radiopharmaceutical with improved pharmacokinetics for human studies. J Nucl Med. 2019;60:26–33. https://doi.org/10.2967/jnumed.118.210294.

4. Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discovery. 2023;22:101–26. https://doi.org/10.1038/s41573-022-00579-0.

5. Altunay B, Morgenroth A, Beheshti M, Vogg A, Wong NCL, Ting HH, et al. HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging. Eur J Nucl Med Mol Imaging. 2021;48:1371–89. https://doi.org/10.1007/s00259-020-05094-1.